Skip to content

Prospective Pilot Study ANDPrecise

AND Precise! : Axillary Lymph Node Dissection and No Drain With the PRECISE Instrument

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02292407
Acronym
ANDPrecise
Enrollment
20
Registered
2014-11-17
Start date
2012-06-30
Completion date
2018-06-30
Last updated
2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This study aims at providing first evidence that axillary clearance by using an operation technique including the precise LigaSure instrument and closure of dead space of the axilla will result in an operation were a drain is not necessary and the need for seroma evacuation after surgery is very limited.

Detailed description

Axillary clearance in breast cancer is usually performed by using a drain to prevent seroma formation and to support obliteration of the dead space in the axillary carry out. The hypothesis made in this protocol is that axillary clearance by using an operation technique including the use of the precise LigaSure instrument and closure of dead space can be done without using a postoperative drain. The AND PRECISE PROTOCOL aims at providing first evidence that axillary clearance by using an operation technique including the precise LigaSure instrument and closure of dead space of the axilla will result in an operation were a drain is not necessary and the need for seroma evacuation after surgery is very limited Patients undergoing axillary clearance necessary for achieving reasonable control in invasive breast cancer and participating in the AND PRECISE protocol will undergo the operation by using a technique including the use of the precise LigaSure instrument and closure of dead space. Postoperatively, the numbers of seroma punctions and the amount of seroma will be recorded prospectively. Patients will be asked to record on a daily basis their experience of pain by a visual analog scale of pain. The main study parameter is the percent of cases which successfully did not need seroma punctions after the intervention. Potential disadvantages for the patient are risk for more seroma formation and discomfort. Patients will be asked to record on a daily basis their experience of pain by a visual analog scale of pain.

Interventions

DEVICELigaSure Precise instrument

LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain

Sponsors

The Netherlands Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Indications for axillary clearance can be a tumor positive sentinel node or tumor positive lymph nodes proven by ultrasound or fine needle aspiration cytology. * For this pilot, only patients undergoing breast conserving surgery are eligible. * Axillary clearance can be performed after previous sentinel node procedure, at the same operation, and after neo-adjuvant chemo therapy, and as secondary procedure in case of axillary relapse after previous treatment for breast cancer.

Exclusion criteria

* Patients undergoing a modified radical mastectomy including an axillary clearance. * Preoperative preexisting seroma.

Design outcomes

Primary

MeasureTime frame
Number of seroma evacuations per patientwithin 3 months after surgery

Secondary

MeasureTime frame
Number of wound infections per patientwithin 3 months after surgery
Number of hematomas per patientwithin 3 months after surgery

Countries

Netherlands

Contacts

Primary ContactEmiel Rutgers, MD, PhD
e.rutgers@nki.nl+3120512

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026